<DOC>
	<DOC>NCT00621855</DOC>
	<brief_summary>The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.</brief_summary>
	<brief_title>RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criteria Patients with acute coronary syndromes with at least one additional risk factor for cardiovascular complications. Exclusion criteria 1. Long term treatment with any other oral anticoagulant 2. Severe/disabling stroke within last 6 months 3. Conditions associated with increased bleeding risk 4. Anaemia or thrombocytopenia 5. Severe renal impairment 6. Liver disease 7. Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>